The emergence of multi-4-lactam resistance is a limiting factor in treating invasive Pseudomonas infections with newer cephalosporins. The in vivo efficacy of ciprofloxacin, a new carboxy-quinolone, was evaluated in experimental aortic valve endocarditis caused by a strain of Pseudomonas aeruginosa which is stably derepressed for ,l-lactamase production and is resistant to ceftazidime and multiple other P-lactam agents. A total of 51 catheterized rabbits with aortic catheters in place were infected with this strain and then received no therapy (controls), ceftazidime (75 mg/kg per day), or ciprofloxacin (80 mg/kg per day). Ciprofloxacin sterilized all blood cultures and significantly lowered vegetation densities of P. aeruginosa by day 2 of treatment versus controls (P < 0.0005) and animals receiving ceftazidime (P < 0.0005). This beneficial effect of ciprofloxacin was also noted on therapy days 6 and 11. Ciprofloxacin rendered most vegetations (85%) culture negative over the 11-day treatment period and achieved bacteriologic cure in 73% of animals (P < 0.0005 versus other therapy groups). Ciprofloxacin prevented bacteriologic relapse at 6 days posttherapy. No ciprofloxacin resistance was detected among Pseudomonas isolates from cardiac vegetations. Ciprofloxacin warrants further evaluation in vivo versus multi-drug-resistant gram-negative bacillary infections.
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Recent experiences in the treatment of Pseudomonas aeruginosa endocarditis in humans and experimental animals have emphasized the difficulties in achieving cures with antibiotics alone, especially in left-sided valve involvement (13) (14) (15) ; K. Rajashekarasah, L. Bhatia, T. Price, J. Kowalski, D. McCulley, and C. Kallick, Program Abstr. 22nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 367, 1982) . This has been related to either primary drug failures or development of resistance in vivo, resulting in recrudescent bacteremia and endocarditis (13) (14) (15) .
One limiting factor in the therapy of endocarditis and other invasive pseudomonal infections has been in vivo development of antibiotic resistance that may cross class lines (e.g., P-lactams --aminoglycosides) (11, 19) . We imental Pseudomonas endocarditis in our laboratory (la, lb); also, this dosage regimen consistently produces supra-MBC serum levels for the infecting Pseudomonas strain at approximately 1 h postinjection. The ceftazidime dosage used in the present investigation was similar to that successfully used in treating experimental Pseudomonas endocarditis previously in our laboratory (2) . Sacrifices. Animals were sacrificed by rapid intravenous injection of 150 mg of sodium pentobarbital on day 2, 6, or 11 of therapy, or 6 days posttherapy to evaluate bacteriologic relapse. At sacrifice, aortic valve vegetations were individually excised, weighed, homogenized, and quantitatively cultured as previously described (2) . No attempt was made to inactivate ceftazidime or ciprofloxacin in vegetation homogenates, as all sacrifices were performed at least 18 h after the final drug dose (16) . Samples of each vegetation homogenate were also quantitatively cultured into MuellerHinton agar containing ceftazidime (50 ,.g/ml) or ciprofloxacin (8 pLg/ml) depending on the therapy regimen. For ciprofloxacin-treated animals, this was to detect in vivo development of resistance to ciprofloxacin; for ceftazidimetreated animals, it was to confirm persistence of ceftazidime resistance in vivo for the duration of the study. The antibiotic concentrations chosen to detect ciprofloxacin or ceftazidime resistance are above the breakpoints for each drug (ceftazidime, 32 ,.g/ml; ciprofloxacin, 2 to 4 ,ug/ml [10; R. Tilton, Proc. 1st Int. Ciprofloxacin Workshop, 1985, in press.]). In addition, 20 selected colonies from antibioticfree culture plates of animal receiving ciprofloxacin were retested for ciprofloxacin MIC and MBC by the broth macrodilution technique. In calculating mean bacterial densities in vegetations, culture-negative vegetations were considered to contain <2 log1o CFU/g based on average vegetation weight of 0.01 g (5) . To delineate the relative proportions of ceftazidime-resistant and ceftazidimesusceptible isolates contained within individual vegetations, a resistance ratio was calculated (6) . This is defined as the log1o of the ratio of the number of resistant organisms to the total number of organisms within a vegetation (log1o [number of resistant isolates/total number of isolates]).
Antibiotic levels. Antibiotic trough and peak levels were determined in serum samples obtained just before and 1 h after drug administrations on day 2 or 3 of therapy. Ceftazidime levels were determined by high-pressure liquid chromatography; ciprofloxacin levels were determined by bioassay. The indicator organism for the ciprofloxacin bioassay was Klebsiella pneumoniae ATCC 10031. The sensitivity of the assay for ceftazidime is 5 jig/ml; that for ciprofloxacin is 0.02 ,ug/ml. The day-to-day variation for the bioassay is 9.49%; that for high-pressure liquid chromatography is 1.4 to 5.1%.
SBTs. All serum bactericidal titers (SBTs) were determined in sera obtained at the 1-h-posttreatment period referred to above, with the microtiter method (12) . The diluent was heat-inactivated (56°C for 30 min), freshly pooled normal rabbit serum. The SBT was defined as the highest serum dilution yielding zero colonies on subculture (>99.9% killing of the original inoculum [12] ).
Statistical evaluation. The chi-square test with Yates correction factor was used for comparing differences in proportions between groups of animals; the two-tailed Student t test was used for comparing the log1o CFU per gram of vegetation in the different therapy groups. A P value of <0.05 was considered significant.
RESULTS
Mortality. Nine animals, four from the control group, three from the ciprofloxacin group, and two from the ceftazidime group, died within 12 h of inoculation and were not included in the data analysis. Mortality rates in the remaining animals, given as the number of animals dying before the assigned sacrifice date/total number analyzed, were as follows: controls, 5/13 (38%); ceftazidime, 4/15 (26%); ciprofloxacin, 2/14 (14%). There were no significant differences among these mortality rates.
Blood cultures. Blood cultures taken 24 h after inoculation were positive for P. aeruginosa in all 42 surviving animals, presumptively confirming induction of endocarditis (1). Blood cultures taken at time of sacrifice were uniformly positive in control animals and remained positive in 9 of the 11 animals (81%) receiving ceftazidime. In contrast, terminal blood cultures were negative in all 12 sacrificed recipients of ciprofloxacin. These frequencies of positive blood cultures were significantly lower in ciprofloxacin-treated animals than in controls or animals receiving ceftazidime (P < 0.005).
Densities of P. aeruginosa in vegetations. All vegetations from untreated controls (n = 30) yielded P. aeruginosa on cultures (no spontaneous cures). The range of bacterial densities in vegetations from these untreated controls (7 to 11 log1o CFU/g) was similar to those previously reported in this model (Table 1) (1-3, 7) .
Ciprofloxacin exerted a rapid bactericidal effect in vivo. By day 2 of therapy, mean vegetation densities from ciprofloxacin-treated animals were <3 log1o CFU/g, as com-VOL. 30, 1986 pared with >8 log10 CFU/g for animals receiving no therapy or ceftazidime (P < 0.0005, ciprofloxacin versus the latter two regimens). This salutary effect of ciprofloxacin in reducing vegetation densities of P. aeruginosa was also seen at days 6 and 11 of therapy. Ciprofloxacin was also very effective at rendering individual vegetations culture negative (Table 1) . Over the 11-day therapy period, 29 of 34 vegetations (85%) in animals given ciprofloxacin were culture negative versus 0 of 33 in animals receiving ceftazidime (P < 0.0005). Moreover, ciprofloxacin rendered all individual vegetations culture negative in 8 of 12 animals (67%) ( Table  1) .
At 6 days after discontinuing antibiotic therapy, all vegetations from ciprofloxacin-treated animals were culture negative; those from animals previously receiving ceftazidime were >7 log10 CFU/g (mean, >9 log10 CFU/g).
Persistence of ceftazidime resistance in vivo. Ceftazidime resistance was stable in vivo. Resistance ratios among P. aeruginosa isolated from cardiac vegetations were low at each sacrifice time (mean ± standard error of the mean = -0.65 + 0.15; range, 0.0 to -4.07). The low resistance ratios confirm that most of the bacterial population within vegetations remained ceftazidime resistant (6) . There were no P. aeruginosa isolated on subculture plates containing 8 ,ug of ciprofloxacin per ml. In addition, in 17 of 20 isolates from antibiotic-free culture plates, retested for ciprofloxacin MIC and MBC, these values remained at pretherapy levels (0.195 ,ug/ml). For the remaining three isolates, the MIC and MBC were each 0.39 ,ug/ml.
SBTs. No serum bactericidal activity was detectable in six of nine serum samples from animals receiving ceftazidime; bactericidal activity was low in the remaining three samples (one each = undiluted, 1:2, and 1:4 SBTs). In contrast, all five serum samples from animals receiving ciprofloxacin exhibited bactericidal activity at .1:8 titer (two at 1:8, three at >1:128 titers).
Serum antibiotic levels. Serum ciprofloxacin levels at 1 h postdosage exceeded the MBC for the infecting Pseudomonas strain by greater than twofold in all determinations (mean ± standard error of the mean = 3.46 ± 1.01 ,ug/ml; range, 0.92 to 8.7 ,ug/ml). Such peak serum concentrations are attainable in humans given 500 to 1,000 mg of ciprofloxacin orally (20) . Mean ceftazidime concentrations were 49 ± 8.3 ,ug/ml (range, 25 to 78 ,ug/ml). No ceftazidime or ciprofloxacin was detectable in serum samples obtained approximately 12 h postdosage (trough samples).
DISCUSSION
Over the last decade, a variety of P-lactamase-stable, extended-spectrum cephalosporins have been developed and put into clinical use, including cefoxitin, cefotaxime, moxalactam, cefoperazone, and ceftazidime (9) . Recently, a number of reports have documented the emergence of resistance during therapy with these agents related to inducible or mutationally derepressed ,-lactamase production (4, 11, 17, 19) . A disturbing feature of the acquired resistance to these newer ,-lactamase-stable cephalosporins has been the development of cross-resistance to multiple other P-lactam antibiotics, as well as the extension of resistance across antibiotic class lines to the aminoglycosides (11) . Of note, this phenomenon has been most commonly observed among genera within the expanded spectrum of newer cephalosporins, especially Enterobacter, Serratia and Pseudomonas species (11, 19) .
Infective endocarditis caused by P. aeruginosa would appear to be an ideal setting for development of such resistance to newer ,B-lactam antibiotics, because of the high in vivo inoculum within cardiac vegetations (>7 to 10 logl0 CFU/g), as well as the possibility for subinhibitory drug levels to exist in certain parts of the vegetation (17) . We have recently encountered such problems with emergence of resistance during therapy of experimental aortic valve Pseudomonas endocarditis (la, 3) . In one study (3) (la, lb) .
The present study showed that: ciprofloxacin exerted a rapid bactericidal effect in vivo by sterilizing all blood cultures and reducing mean vegetation counts of Pseudomonas >5 logl0 CFU/g below those seen in untreated controls and animals receiving ceftazidime; ciprofloxacin prevented bacteriologic relapse in animals evaluated at 6 days after discontinuation of therapy; ciprofloxacin effected an overall bacteriologic cure in two-thirds of animals receiving this agent; and no ciprofloxacin resistance developed in vivo. This lack of development of ciprofloxacin resistance in vivo was also noted in our previous studies of the efficacy of ciprofloxacin in experimental Pseudomonas endocarditis caused by the parental strain (PA-96) from which PA-48 was derived (la, lb) .
With the increasing reports of multi-1-lactam and aminoglycoside resistances emerging during therapy with extended-spectrum cephalosporins, new quinolone antibiotics may become important components of the therapeutic arsenal. One note of caution, however, emanates from the recent study of Sanders, who observed P-lactam-quinolone cross resistances in laboratory-derived mutants of K. pneumoniae (18) . The frequency of such P-lactam-quinolone or ,3-lactamaminoglycoside-quinolone cross resistance needs to be further delineated among clinically derived isolates.
